Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Helix BioPharma (HBP) Stock Price & Analysis

32 Followers

HBP Stock Chart & Stats

CA$0.85CA$0.00(0.00%)
At close: 4:00 PM EST
C$1C$1.5C$2Aug 17Aug 31Sep 14Sep 28Oct 13Oct 26Nov 10
Day’s Range
CAD 0.85 - CAD 0.86
52-Week Range
CAD 0.75 - CAD 2.60
Previous Close
CAD 0.85
Volume
N/A
Average Volume (3M)
5,841
Market Cap
CAD 64.92M
Enterprise Value
CAD 117.92M
Total Cash (Recent Filing)
CAD 804.00K
Total Debt (Recent Filing)
CAD 4.16M
Price to Earnings (P/E)
―
Beta
2.46
Next Earnings
Dec 16, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Improved Equity Base

The return to positive equity and moderate leverage indicates meaningful recapitalization and improved solvency versus prior years. This provides a stronger financial foundation for continued drug development and may reduce balance-sheet pressure over the next several quarters.

Narrowing Losses

The substantial reduction in annual net loss suggests better expense control and a lower rate of financial deterioration. Although the company remains unprofitable, continued improvement could extend its operating runway and make future funding requirements more manageable.

Improving Cash-burn Trend

A steadily less negative free-cash-flow profile indicates that cash consumption has moderated from earlier periods. This does not yet represent self-funding, but sustained improvement would preserve capital longer and support ongoing development before a revenue base is established.

Bears Say

No Revenue Base

The absence of revenue means Helix BioPharma has not yet demonstrated commercial demand or an internally funded operating model. Its clinical-stage programs must therefore progress substantially before the business can build recurring sales and reduce dependence on external capital.

Persistent Cash Dependence

Persistent operating cash burn limits financial flexibility and requires continued access to financing while development work proceeds. If external funding becomes less available, the company could face pressure to slow programs or raise capital on unfavorable terms.

Rising Debt Amid Losses

The sharp increase in debt adds fixed financial obligations to a business that still has no revenue and negative profitability. Greater leverage can constrain future capital allocation and increase financial risk if losses persist or development spending remains elevated.

Helix BioPharma News

HBP FAQ

What was Helix BioPharma’s price range in the past 12 months?
Helix BioPharma lowest stock price was C$0.75 and its highest was C$2.60 in the past 12 months.
What is Helix BioPharma’s market cap?
Helix BioPharma’s market cap is C$64.92M.
When is Helix BioPharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Helix BioPharma’s earnings last quarter?
Helix BioPharma released its earnings results on Oct 29, 2026. The company reported -C$0.013 earnings per share for the quarter.
Is Helix BioPharma overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Helix BioPharma pay dividends?
Helix BioPharma does not currently pay dividends.
What is Helix BioPharma’s EPS estimate?
Helix BioPharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Helix BioPharma have?
Helix BioPharma has 76,378,100 shares outstanding.
What happened to Helix BioPharma’s price movement after its last earnings report?
Helix BioPharma reported an EPS of -C$0.013 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Helix BioPharma?
Currently, no hedge funds are holding shares in TSE:HBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology